ALLR · Allarity Therapeutics, Inc.

This 8-K filing conveys a high-materiality operational milestone: Allarity Therapeutics has confirmed that its stenoparib active pharmaceutical ingredient (API) manufacturing campaign is progressing per plan at a European contract development and manufacturing organization (CDMO) operating under both FDA and EMA Good Manufacturing Practice standards. Completion is expected no later than the third quarter of 2026 — a firm, externally anchored timeline that directly supports the Company’s stated intent to advance into a pivotal trial for advanced ovarian cancer. Critically, the filing states that all manufacturing-related payments have been completed and no additional cash outlays for manufacturing are anticipated, materially reducing near-term financial execution risk and enhancing visibility into cash runway. The timing is strategically significant: the campaign is designed to deliver API meeting late-stage clinical standards well in advance of the anticipated data readout from the ongoing Phase 2 trial in platinum-resistant ovarian cancer — enabling rapid progression without supply constraints. Management explicitly ties this milestone to the FDA Fast Track designation, framing it as a key enabler for accelerated development and potential approval. While no financial results or guidance are disclosed in this filing, the manufacturing readiness update carries substantial operational and regulatory weight, directly addressing investor concerns around drug supply, development timing, and capital efficiency — all central to valuation in a clinical-stage biopharma context.